Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends 2025-2034: Insights into Growth and Strategic Opportunities Ahead
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Will the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market’s Growth Rate Evolve Over the Forecast Period to 2034?
The market of alpha-1 antitrypsin deficiency augmentation therapy has witnessed robust expansion in the past few years. Its size is projected to escalate from $1.69 billion in 2024 to $1.82 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.3%. Factors such as enhanced diagnostic procedures, public awareness drives, clinical research, and the rise in the ageing population have contributed to its growth in the preceding period.
There is an anticipated firm growth in the alpha-1 antitrypsin deficiency augmentation therapy market size over the next several years. With a compound annual growth rate (CAGR) of 7.9%, it is projected to increase to $2.47 billion by 2029. Contributing factors to this growth throughout the projected period are advancements in telehealth and remote monitoring, precision medicine, and gene therapy. Key trends for this period consist of data related to long-term safety and effectiveness, models of care centered around the patient, programs of tele-rehabilitation, and personalized dosing regimens.
How Are the key drivers expanding the growth of the alpha-1 antitrypsin deficiency augmentation therapy Market?
The escalation in the occurrence of respiratory diseases is considered a significant factor contributing to the expansion of the alpha-1 antitrypsin deficiency augmentation therapy market. These diseases, which impact the lungs and respiratory system, result in chaotic breathing and a diminished lung function. The purpose of alpha-1 antitrypsin deficiency augmentation therapy is to remediate these diseases by supplementing the insufficient protein in those suffering from alpha-1 antitrypsin deficiency. This therapy attains this by normalizing protease-antiprotease activity in the lungs, safeguarding lung tissue from harm induced by heightened neutrophil elastase activity, and the reduction of inflammation. As an illustration, the United States reported a rise in tuberculosis (TB) cases from 7,874 in 2021 to 8,300 in 2022, as stated by the Centers for Disease Control and Prevention in March 2023. Consequently, the surge in respiratory diseases has led to a robust growth for the alpha-1 antitrypsin deficiency augmentation therapy market. Growth in the alpha-1 antitrypsin deficiency augmentation therapy market is expected due to a rise in the number of clinical trials. Clinical trials are forms of research, using human participants, that explore and compare biomedical or behavioral interventions, including new and known treatments, to answer essential health-related questions. Critical to the creation and authorization of unique treatments for AATD, an increase in clinical trials illustrates an uptick in the interest in developing novel therapies for AATD. This could result in the emergence of improved treatments. In May 2023, Xtalks, a Canada-based news and information network, reported 452,604 clinical studies registered on ClinicalTrials.gov, a significant increase from just over 365,000 in 2021. This spike in the number of clinical trials makes a compelling case for the anticipated growth of the alpha-1 antitrypsin deficiency augmentation therapy market.
Get Your Free Sample of the Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp
Who Are the Influential Players Reshaping the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Landscape?
Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are:
• Pfizer Inc._x000D_
• Sanofi S.A._x000D_
• AstraZeneca PLC_x000D_
• GlaxoSmithKline PLC_x000D_
• Takeda Pharmaceutical Company Limited_x000D_
What New and Evolving Trends Are Having a Lasting Impact on the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
Leading enterprises in the acute respiratory distress syndrome (ARDS) market are strategically focusing on the development of novel therapies, such as those based on recombinant technology, in order to preserve their market standing. Recombinant DNA technology is employed for the generation of therapeutic drugs via recombinant technology-based drug development. This process involves the alteration of DNA in living organisms to create specific proteins. For example, Inhibrx Inc., a biotechnology firm based in the US, announced in March 2022 that INBRX-101 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the management of alpha-1 antitrypsin deficiency (AATD). INBRX-101 is a recombinant human AAT-Fc fusion protein that may enable a once-monthly dosage and is expected to safely attain and maintain AAT levels consistent with those of healthy individuals.
Get Instant Access to the Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report with Swift Delivery!
How Are the Key Segments of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Impacting Its Expansion and Revenue Streams?
The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented –
1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza
2) By Route Of Administration: Oral, Injection, Inhalation
3) By End User: Hospitals, Specialty Clinics, Other End Users
Which Geographic Locations Are Critical to the Growth of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Key Characteristics That Define the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
Alpha-1 antitrypsin deficiency augmentation therapy is a medical treatment that involves infusing purified alpha-1 antitrypsin protein into individuals with deficient levels to protect the lungs from damage caused by an imbalance of protease and antiprotease enzymes. It aims to slow the progression of emphysema and improve lung function in affected patients.
Browse Through More Similar Reports By The Business Research Company:
Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024
Respiratory Disposables Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report
TNF Alpha Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/tnf-alpha-inhibitor-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
